Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Significant default risk
Profitability factor
Undervalued vs peers
Favourable analyst view
Very low or no dividends
Risk / Profitability
Risk: High
Profitability: Favourable
Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Significant default risk
Profitability factor
Undervalued vs peers
Favourable analyst view
Very low or no dividends
$ 12.01
About
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial...
About
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated...
